Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MultiTAA-specific T cells |
Synonyms | |
Therapy Description |
MultiTAA-specific T cells are T-lymphocytes that have been treated with dendritic cells exposed to a cocktail of tumor-associated antigens (TAAs) such as WT1, PRAME, NY-ESO1, MAGEA4 and Survivin, which have potential antitumor activity against tumors expressing TAAs (Blood (2015) 126 (23): 186; Blood (2017) 130 (Supplement 1): 164). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MultiTAA-specific T cells | TAA-CTL|TAA-T|TAA-specific CTLs | MultiTAA-specific T cells are T-lymphocytes that have been treated with dendritic cells exposed to a cocktail of tumor-associated antigens (TAAs) such as WT1, PRAME, NY-ESO1, MAGEA4 and Survivin, which have potential antitumor activity against tumors expressing TAAs (Blood (2015) 126 (23): 186; Blood (2017) 130 (Supplement 1): 164). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02475707 | Phase I | MultiTAA-specific T cells | Administration of Donor MultiTAA-Specific T Cells for ALL (STELLA) | Active, not recruiting | USA | 0 |
NCT03652545 | Phase I | MultiTAA-specific T cells | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) | Recruiting | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT05134740 | Phase I | MultiTAA-specific T cells | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | Withdrawn | USA | 0 |
NCT02494167 | Phase I | MultiTAA-specific T cells | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | Recruiting | USA | 0 |
NCT02291848 | Phase I | MultiTAA-specific T cells | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM) | Recruiting | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
NCT01333046 | Phase I | MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) | Active, not recruiting | USA | 0 |
NCT03192462 | Phase Ib/II | MultiTAA-specific T cells | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS) | Active, not recruiting | USA | 0 |
NCT03093350 | Phase II | MultiTAA-specific T cells | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC) | Active, not recruiting | USA | 0 |